Research Scientist
Moffitt Cancer Center
Rafael Renatino Canevarolo, Ph.D., is a Research Scientist II in the Silva Lab at the H. Lee Moffitt Cancer Center & Research Institute in Tampa, Florida. He earned his Ph.D. in Sciences from the State University of Campinas (UNICAMP), Brazil, and completed his postdoctoral training at Moffitt, focusing on drug resistance, molecular characterization in multiple myeloma (MM) onset and progression.
Dr. Canevarolo’s research centers on uncovering therapeutic vulnerabilities in MM by integrating high-throughput ex vivo drug screening with bulk and single-cell multi-omic profiling. He has contributed to numerous collaborative projects that explore tumor evolution, metabolic reprogramming, epigenetic plasticity, and mechanisms of resistance to therapy in MM. His recent work includes the application of scMultiome, transcriptomic modeling, and systems biology to map regulatory networks driving disease progression.
He is co-inventor on five patents and co-author of over 25 peer-reviewed publications in journals including Nature Communications, Cancer Research, and Blood Advances. His work has been recognized through multiple awards at national and international conferences, including honors from the American Society of Hematology (ASH), the NCI Physical Sciences-Oncology Network (PS-ON), and other scientific symposia across the Americas.
Dr. Canevarolo frequently collaborates with clinical and translational teams at Moffitt and external institutions to bridge laboratory insights with patient-centered outcomes. He is passionate about advancing precision oncology through collaborative science and data-driven strategies.
In addition to his research, Dr. Canevarolo has mentored and supervised numerous graduate and undergraduate students and served as an ad hoc reviewer for various scientific journals. He has participated in nearly 40 scientific conferences and received a competitive fellowship to support his graduate training in Brazil, reflecting his long-standing commitment to academic excellence and scientific dissemination.